CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.
CTAD 2022 – lecanemab data hold up, with a big but
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
Ash 2022 preview – Brukinsa has the edge over Calquence
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
Ash 2022 preview – Novartis has Apellis in its sights
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
SABCS 2022 preview – now Arvinas’s degrader takes a knock
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
Ash 2022 preview – Argenx’s expansion plans come into focus
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
AHA 2022 – Idorsia and Cincor move forward in hypertension
Aprocitentan’s effect size falls short of expectations, raising the risk that J&J might cool on its Idorsia partnership, while Cincor remains one to watch.
